Medical Marijuana Inc (OTCMKTS:MJNA) reported that its major investment firm Axim Biotechnologies Inc (OTCMKTS:AXIM) has finalized a Term Sheet Deal with an active pharmaceutical ingredient production firm to advance a chewing gum product depending on AXIM IP and technology. The latest dronabinol chewing gum offering is projected to be bioequivalent to Marinol®, a product which was first launched in the U.S. industry in 1985 and continues to be the only FDA accepted cannabis-based medicine available in the United States.
Medical Marijuana reported that marinol is used to cure vomiting and nausea caused by cancer chemotherapy. It is commonly used when other medicines to control vomiting and nausea have failed. Dronabinol is also utilized to cure weight loss and loss of appetite in subjects with HIV infection. Dronabinol is a man-made type of the active natural ingredient in marijuana. AXIM will look for these same signs in its clinical research on the new replacement product.
In its existing form, Marinol is administered via a gel capsule where a big part of the dronabinol is absorbed into 11-OH- THC following the first-pass metabolism. This results in adverse side effects for patients such as impaired thinking. AXIM’s control-release chewing gum mainly bypasses the initial pass metabolism in the liver to the extent where AXIM considers their new formulation will enhance efficacy while simultaneously minimizing side effects for people who use this new delivery process.
AXIM will coordinate with an API-manufacturing firm that will offer AXIM with delta-9-THC for use in these studies. It will then perform a bio-equivalency trial and will eventually look for FDA nod to bring this replacement product to market.
Dr. Stuart Titus, PhD, the CEO of Medical Marijuana, reported that AXIM has expanded its clinical research plan in an important and impressive way that will immensely benefit related patients’ population.